Overall survival with cisplatin and 5-fluorouracil neoadjuvant treatment in patients with esophageal cancer: Single-center experience

Onkologie

Volumn 31, Issue 12, 2008, Pages 673-677

  Idelevich, Efraim ^a   Buyevich, Victor ^a   Machlenkin, Svetlana ^a   Ziv Sokolovsky, Nadya ^a   Dinerman, Michael ^a   Brenner, Baruch ^b   Kashtan, Hanoch ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

5 Fluorouracil; Cisplatin; Esophageal cancer; Neoadjuvant treatment; Survival

Indexed keywords

CISPLATIN; DEXAMETHASONE; FLUOROURACIL; ONDANSETRON;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; POSTOPERATIVE CARE; SURGICAL APPROACH; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; ISRAEL; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREVALENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 57449097184     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000165056     Document Type: Article

References (20)

1. Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, Fremgen AM: Esophageal cancer: results of an American College of Surgeon Patient Care evaluation study. J Am Coll Surg 2000;190:562-573.
2. Ellis FH, Heatley GJ, Krasna MJ, Williamson WA, Balogh K: Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg 1997;13:836-846.
3. Medical Research Council Oesophageal Cancer Working Party: Surgical Resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 2002;359:1727-1733.
4. Kelsen DP, Ginsberg R, Pajak T, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA: Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-1984.
5. Law S, Fok M, Chow S, Chu KM, Wong J: Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997;114:210-217.
6. Darnton SJ, Archer VR, Stocken DD, Mulholland PJ, Casson AG, Ferry DR: Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol 2003;21:4009-4015.
7. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, Zaninotto G, Bonavina L, Peracchia A: Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. Cancer 2001;91:2165-2174.
8. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG, Radiation Therapy Oncology Group, USA Intergroup: Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007;25:3719-3725.
9. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO Off-set Publication No. 4, Geneva, Switzerland, 1979.
10. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0, DCTD, NCI, NIH, DHHS, March 31, 2003. http://ctep.cancer.gov/reporting/ ctc_v30.html.
11. Pouliquen X, Levard H, Hay JM, McGee K, Fingerhut A, Langlois-Zantin O: 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Association for Surgical Research. Ann Surg 1996;223:127-133.
12. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS: Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003;10:754-761.
13. Bader FG, Lordick F, Fink U, Becker K, Hofler H, Busch R, Siewert JR, Ott K: Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up. Onkologie 2008;31:366-372.
14. Pennathur A, Luketich JD, Landreneau RJ, Ward J, Christie NA, Gibson MK, Schuchert M, Cooper K, Land SR, Belani CP: Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg 2008;85:1930-1936.
15. Safranek PM, Sujendran V, Baron R, Warner N, Blesing C, Maynard ND: Oxford experience with neoadjuvant chemotherapy and surgical resection for esophageal adenocarcinomas and squamous cell tumors. Dis Esophagus 2008;21:201-206.
16. Halliday BP, Skipworth RJ, Wall L, Phillips HA, Couper GW, de Beaux AC, Paterson-Brown S: Neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophago-gastric junction: a six-year experience. Int Semin Surg Oncol 2007;4:24.
17. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
18. Kelsen DP, Ilson DH: Chemotherapy and combined-modality therapy for esophageal cancer. Chest 1995;107:224-232.
19. Polee MB, Tilanus HW, Eskens FALM, Hoekstra R, Van der Burg ME, Siersema PD, Stoter G, Van der Gaast A: Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus. Ann Oncol 2003;14:1253-1257.
20. Hulscher JBF, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ: Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002;347:1662-1669.